

Modelagem de Merger & Acquisitions (M&A) na Avaliação de Expansão de Centros de Pesquisa

Gustavo Kesselring – Strategy Advisor Care Access LATAM



ACESSE

ASSOCIAÇÃO BRASILEIRA DE
CENTROS DE PESQUISA CLÍNICA





Tópicos

Cenário internacional

Como avaliar o valor de um centro de pesquisa ?

Pontos de avaliação –fatores chaves

Análise financeira

Análise operacional

Métodos de avaliação

Exemplo hipotético


Clinical Trials Industry Landscape | Trends of Diseases in Clinical Trials

Chronic Diseases (Diabetes/ Obesity / Imuno related)


CLINICAL TRIAL ACTIVITY

Obesity clinical trials in 2023 were up by 68% from 2022, and nearly doubled when compared to 5 years ago

Exhibit 19: Industry sponsored interventional trials by start date, 2014-2023



Source: Citeline Trialtrave, Jan 2024; IQVIA Institute, Jan 2024.



Clinical Trials Industry Landscape | Site Landscape

Market Consolidation & Competitive Landscape

Clinical Research Site Consolidation


Consolidation in the clinical research site marketplace is accelerating

Key Commentary

- With 20,000+ different clinical research sites and only 500 – 600 corporate units, we are early in the consolidation wave
- However, a large subset of independent operators will choose to remain independent, do not fit the criteria for acquisition, or are part of a large physician practice, thus limiting the number of actionable sites for acquisition
- Accelerating consolidation will increase competition among site platforms and drive increased demand for more sophisticated therapeutic areas and clinical research capabilities

Market Consolidation Trend

Continued consolidation has resulted in ~3% professionally owned and managed sites with ~15% global market share



Source: Industry Reports; Edgemont Proprietary Intelligence.

Top Consolidators

Platform	Ownership	Estimated Current Sites
Accellacare	ICON Pfizer Health Sciences	80+
Velocity CLINICAL RESEARCH	QMS GMS	80+
AES Accelerated Enrollment Solutions	PPD ThermoFisher Scientific	75+
ALCANZA CLINICAL RESEARCH FOR ALL	MARTIS CAPITAL	35
ERG Evolution Research Group	LINDEN ¹	26
AMR ALLIANCE FOR MARKET SPECIALTY RESEARCH	CUREWELL CAPITAL LIT EQUITY PARTNERS	20
CenExel CLINICAL RESEARCH	Webster Equity Partners	18
Headlands RESEARCH	KKR	16
FLOURISH RESEARCH	NMS CAPITAL	13
All Platforms		500 – 600

Recent Market Evolution

Then, a global pandemic struck...

- Today, less than four years later, we count nearly 30 PE-backed platforms, which in aggregate now represent an estimated ~15% of the global market, with eight of these platforms recapitalized in the last ~12 months

Selected M&A Add-On Activity	2016	2017	2018	2019	2020	2021	2022	2023	Total
ERG Evolution Research Group	1	2	1	1	1	-	1	-	7
Velocity CLINICAL RESEARCH	-	2	1	2	3	5	5	-	18
CenExel CLINICAL RESEARCH	-	-	2	3	-	3	4	-	12
Headlands RESEARCH	-	-	-	4	2	2	1	3	12
IMA THE IMA GROUP	-	-	-	1	-	3	1	2	7
FLOURISH RESEARCH	-	-	-	-	-	2	3	2	7
ALCANZA CLINICAL RESEARCH FOR ALL	-	-	-	-	-	1	4	2	7
IQVIA	-	-	-	-	-	-	-	2	2

Source: Edgemont Proprietary Intelligence.

EDGEMONT

CLINICAL RESEARCH SITE MARKET OVERVIEW | JANUARY 2024

2

Clinical Trials Industry Landscape | Site Landscape

Market Consolidation & Competitive Landscape

THE RISE OF THE CLINICAL TRIAL SITE MEGA NETWORK

Scaling and Innovating Part 3:
Site Network Consolidation
by the Numbers



CRIO

WEBINAR DETAILS


Title: Clinical Trial Sites: The Rise of the Mega Network

Date: April 10, 2024

Segment	#	Rev (\$M)	Share	Avg (\$M)
Enterprise (Financial/Strategic)	45	\$1,350	38%	\$30
Mid Market (\$1M rev & up)	600	\$1,650	46%	\$3
Small (Sub \$1M rev)	4000	\$600	17%	\$0.1-\$0.2
Total	~4,645	\$3,600	100%	\$0.7

Evolving Clinical Research Site Models

Sites operate on a standalone, embedded, hybrid, or decentralized basis





Avaliação de um centro de pesquisa

- Vendedor : **Quanto será que vale meu centro ? – Expectativa**
- Comprador : **Métricas de mercado – Realidade**

Avaliação de um Centro de Pesquisa

Fatores chaves

- N de estudos ativos e patrocinadores
- Performance de recrutamento de pacientes
- Receita por estudo / por paciente
- Resultado de auditorias regulatórias / patrocinadores (Qualidade de dados)
- Relacionamento com CROs e pharma
- **PI / Sub PI – continuidade pós M&A**

Análise operacional

- Tempo para recrutar primeiro paciente (FPI)
- Media de recrutamento por mês
- Media de screen failure
- Turnover de staff
- Compliance de SOPs
- Tempos regulatórios de aprovação de estudos (IRB)

Análise financeira

- Receita por paciente / Fees de start up / fees de retenção /
- Pipeline de estudos e backlog
- Custos diretos (Folha pgto / PIs e sub PIs fees)
- Overhead (aluguel , adm, seguros)
- Custos de infraestrutura (equipamentos , sistemas eletronicos de prontuario)
- **Sistema contábil adequado e auditável com análise dos últimos 3-5 anos**
- **Indicadores de rentabilidade (EBITDA* , margem por estudo)**
- **EBITDA = lucro antes de juros, impostos , depreciação e amortização**

Métodos de avaliação

- Faturamento e DCF (Discounted Cash Flow)
- **Comparações com o mercado e múltiplos de EBITDA**
- Baseado em assets (equipamentos, softwares , facilities e contratos)

Exemplo de avaliação hipotética

Centro com faturamento bruto de 1 M Reais/ano – 15 trials

Margem EBITDA : 30%

Metodologia usada : múltiplo de EBITDA (5x)

$30\% \times 1 \text{ M Reais} \times 5 = 1,5 \text{ M Reais}$

Valuation = 1,5 M Reais (*) sujeito a negociação





Envie suas dúvidas, perguntas e sugestões
para o nosso WhatsApp!
(21) 98080-2222

Obrigado

ACESSE

ASSOCIAÇÃO BRASILEIRA DE
CENTROS DE PESQUISA CLÍNICA

Contato

gustavo.kesselring@careaccess.com



Care Access



ACESSE

ASSOCIAÇÃO BRASILEIRA DE
CENTROS DE PESQUISA CLÍNICA